SAS Output

13-JUL-2020 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 960 362 180 86 30 4 BREAST
        960 362 180 86 30 4  
 
  2 Y 2 Observation 417 163 81 38 16 3  
      3 MK-3475 (Pembrolizumab) 409 157 79 36 12 6  
        826 320 160 74 28 9  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 212 87 40 16 10 4 SURV
        212 87 40 16 10 4  
 
  2 Y 1 Carvedilol 39 16 6 1 0 0  
      2 No prophylaxis 40 19 8 4 2 1  
      3 Observation 118 47 21 8 4 1  
        197 82 35 13 6 2  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 T 1 Blinded Nutrition Drink 5 3 0 0 0 0 SXQOL
      2 Blinded Nutrition Drink 10 4 0 0 0 0  
        15 7 0 0 0 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 253 107 73 30 9 2 GU
      2 Tokyo-172 BCG 253 108 73 32 9 3  
      3 Prime + Tokyo-172 BCG 255 109 75 35 13 3  
        761 324 221 97 31 8  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y 4 SOC HBV Treatment 2 2 2 1 0 0 SXQOL
        2 2 2 1 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 142 81 41 18 7 1 CCD
        142 81 41 18 7 1  
 
  2 Y 1 Control (Usual Care) 39 26 14 9 3 0  
      2 Intervention (STMDDM) 42 28 18 10 5 1  
        81 54 32 19 8 1  
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes 1 Y 1 Observation 339 325 202 78 32 9 SXQOL
        339 325 202 78 32 9  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 215 140 65 34 14 2 GU
        215 140 65 34 14 2  
 
  2 Y 1 Standard Systemic Therapy Only 73 55 27 15 3 1  
      2 SST + Surgery/RT 70 51 26 12 1 0  
        143 106 53 27 4 1  
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 84 83 47 26 7 3 GU
        84 83 47 26 7 3  
 
  2 Y 1 Chemo + RT 39 38 23 11 2 0  
      2 Chemo + RT + Atezolizumab 36 36 20 11 4 2  
        75 74 43 22 6 2  
 
S1820-Rectal, Diet modification to manage GI sx 1 Y 0 Run-In 20 20 20 17 10 2 PEOLC
        20 20 20 17 10 2  
 
  2 Y 1 Diet Modification Coaching 4 4 4 4 3 2  
      2 Healthy Living Education 5 5 5 4 1 1  
        9 9 9 8 4 3  
 
S1823-GCT, Obs. Cohort, miRNA371 1 Y   0 0 0 0 0 0 PREV
        0 0 0 0 0 0  
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD 1 Y 1 Nivolumab + AVD 75 75 56 30 9 1 LYMPH
      2 Brentuximab Vedotin + AVD 74 74 57 28 9 2  
        149 149 113 58 18 3  
 
S1827-SCLC, MRI Surveillance +/- PCI 1 Y 1 PCI + MRI brain surveillance 1 1 1 1 0 0 LUNG
      2 MRI brain surveillance 4 4 4 4 3 1  
        5 5 5 5 3 1  
 
S1916-Pain, Mets, Opioid Digital Medicine Pilot 1 Y 1 Percocet-DMP 2 2 2 0 0 0 CCD
        2 2 2 0 0 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 607 32 10 5 2 1 PREV
        607 32 10 5 2 1  
 
  1 Y 1 Blinded drug 102 10 5 2 2 1  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 105 21 6 1 1 0  
        278 31 11 3 3 1  
 

13-JUL-2020 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1823-GCT, Obs. Cohort, miRNA371 regtype: 1